Evaluation of a Test Dose Strategy for Pharmacokinetically-guided Busulfan Dosing for Hematopoietic Stem Cell Transplant

Busulfan has been used as a component of conditioning regimens in hematopoietic stem cell transplant (HCT) since the 1950 ’s. Since then, formulations and dosing regimens have evolved.1 Limitations to the use of oral busulfan include inter- and intrapatient variability in exposure, the need for frequent dosing, and increased first-pass metabolism, potentially increasing the rate of sinusoidal obstruction syndrome (SO S) and other toxicities.2-4 Intravenous (IV) busulfan improves the pharmacokinetic (PK) variability, can be administered once daily, and reduces the toxicity profile.

Source: Biology of Blood and Marrow Transplantation - September 19, 2018 Category: Hematology Authors: Jessica Michaud Davis, Anastasia Ivanova, Yunro Chung, J. Ryan Shaw, Kamakshi Rao, Jonathan PtachcinskidAndrew Sharf, Jonathan Serody, Paul Armistead, William A Wood, James Coghill, Katarzyna Jamieson, Benjamin G Vincent, Marcie Riches, Thomas Shea, Mauri Source Type: research